Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.1K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunological mechanisms and therapeutic advances in chronic myeloid leukemia.

Leukemia·2026
Same author

Expert consensus definition of treatment intolerance in chronic myeloid leukemia in chronic phase.

Hematology (Amsterdam, Netherlands)·2025
Same author

The promise of allosteric kinase inhibition.

Blood·2024
Same author

Absence of ABL1 exon 2-encoded SH3 residues in BCR::ABL1 destabilizes the autoinhibited kinase conformation and confers resistance to asciminib.

Leukemia·2024
Same author

BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib.

Blood·2024
Same author

Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREE.

British journal of haematology·2023

Related Experiment Video

Updated: May 13, 2025

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.1K

How I individualize frontline treatment for chronic-phase CML.

Ariel Monet Leyte-Vidal1,2, Neil P Shah2

  • 1Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, FL.

Blood
|April 16, 2025
PubMed
Summary
This summary is machine-generated.

Choosing the best initial therapy for chronic myeloid leukemia (CML) involves balancing effectiveness, tolerability, and long-term outcomes. Patients with CML now have multiple targeted treatment options, improving survival rates.

More Related Videos

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation
09:09

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation

Published on: November 10, 2017

8.2K
Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.0K

Related Experiment Videos

Last Updated: May 13, 2025

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.1K
Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation
09:09

Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation

Published on: November 10, 2017

8.2K
Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.0K

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Chronic myeloid leukemia (CML) treatment has advanced significantly with targeted therapies.
  • BCR::ABL1 tyrosine kinase inhibitors (TKIs) are highly effective for newly diagnosed chronic phase CML.
  • Current CML therapies offer excellent long-term survival, comparable to age-matched controls.

Purpose of the Study:

  • To review the landscape of frontline targeted therapies for chronic myeloid leukemia.
  • To discuss key factors influencing the choice of initial CML treatment.
  • To highlight the importance of balancing efficacy with patient quality of life and treatment costs.

Main Methods:

  • Review of existing literature on CML treatment guidelines and clinical trial data.
  • Analysis of the efficacy, tolerability, and long-term outcomes of available BCR::ABL1 TKIs.
  • Discussion of patient-centered factors in treatment selection.

Main Results:

  • Five effective and well-tolerated BCR::ABL1 TKIs are available for newly diagnosed chronic phase CML.
  • Long-term survival for CML patients is now excellent, approaching that of the general population.
  • Lifelong treatment is typically required for most CML patients.

Conclusions:

  • The selection of frontline CML therapy requires careful consideration of multiple factors beyond initial efficacy.
  • Response durability, tolerability, quality of life, and toxicity avoidance are critical.
  • Treatment administration ease and cost are increasingly important considerations for patients and healthcare systems.